UroGen Pharma Ltd.
URGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $456,637 | $432,515 | $202,296 | $212,525 |
| - Cash | $171,987 | $95,002 | $55,408 | $44,360 |
| + Debt | $123,387 | $100,214 | $100,064 | $398 |
| Enterprise Value | $408,037 | $437,727 | $246,952 | $168,563 |
| Revenue | $90,398 | $82,713 | $64,357 | $48,042 |
| % Growth | 9.3% | 28.5% | 34% | – |
| Gross Profit | $81,517 | $73,352 | $56,703 | $42,885 |
| % Margin | 90.2% | 88.7% | 88.1% | 89.3% |
| EBITDA | -$95,353 | -$60,352 | -$76,214 | -$91,461 |
| % Margin | -105.5% | -73% | -118.4% | -190.4% |
| Net Income | -$126,874 | -$102,244 | -$109,783 | -$110,820 |
| % Margin | -140.4% | -123.6% | -170.6% | -230.7% |
| EPS Diluted | -2.96 | -3.55 | -4.79 | -4.96 |
| % Growth | 16.6% | 25.9% | 3.4% | – |
| Operating Cash Flow | -$96,766 | -$76,376 | -$87,559 | -$84,892 |
| Capital Expenditures | -$295 | -$194 | -$254 | -$752 |
| Free Cash Flow | -$97,061 | -$76,570 | -$87,813 | -$85,644 |